Compare Immunovant Inc. Common Stock (IMVT) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs Plby Group Inc — how do they compare? Immunovant Inc. Common Stock trades at $30.41 (market cap $6.25B), while Plby Group Inc trades at $0.97 (market cap $118.21M). The key difference: Immunovant Inc. Common Stock is far larger — about 52.9× Plby Group Inc's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and Plby Group Inc for 24 Days on average.
| IMVT | PLBY | |
|---|---|---|
Market Cap | $6.25B | $118.21M |
Volume | 1,755,411 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $2.71 |
52-Week Low | $17.03 | $0.99 |
Typical Hold Time | 0 Days | 24 Days |
Enterprise Value | $5.35B | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
PLBY trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $12.67 million in 2025, though revenue grew to $120.93 million and the net loss narrowed significantly from prior years. Recent news highlights leadership appointments aimed at driving brand growth. The stock has a high P/E ratio of 49.34 but a reasonable P/S of 0.87, and analyst consensus is strongly bullish with 75% buy ratings.
The outlook is mixed: improving profitability trends and positive analyst sentiment offer potential upside, but high debt levels, negative shareholder equity, and bearish technicals pose significant risks. Investors should weigh the company's growth initiatives against its financial leverage and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
